Huperzine A
- Generic Name
- Huperzine A
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C15H18N2O
- CAS Number
- 102518-79-6
- Unique Ingredient Identifier
- 0111871I23
- Background
Huperzine A, is a naturally occurring sesquiterpene alkaloid found in the extracts of the firmoss Huperzia serrata. The botanical has been used in China for centuries for the treatment of swelling, fever and blood disorders. Recently in clinical trials in China, it has demonstrated neuroprotective effects. It is currently being investigated as a possible treatment for diseases characterized by neurodegeneration – particularly Alzheimer’s disease.
- Indication
Investigated for use/treatment in alzheimer's disease.
- Associated Conditions
- -
- Associated Therapies
- -
Memoforce Review (2025) Should Retailers Trust Official Memo Force Website Claims?
Memoforce is a natural supplement aimed at enhancing memory and cognitive function through ingredients like Ginkgo Biloba and Phosphatidylserine. It promises improved memory recall, focus, and reduced brain fog, supported by scientific research. Available exclusively online, it offers various pricing plans and a 180-day money-back guarantee. While not FDA approved, it adheres to Good Manufacturing Practices.
Memoforce Reviews: Shocking Warning About Ingredients, Complaints, Side Effects
Memoforce is a natural dietary supplement aimed at enhancing memory, cognitive function, and brain health. It contains ingredients like Ginkgo Biloba, Bacopa Monnieri, and Huperzine-A, known for their cognitive benefits. Users report improved memory recall, focus, and mental clarity. Available exclusively online, it offers a 180-day money-back guarantee.
Memoforce Reviewed (January 2025 Medical Supplement Warning Report)
Memoforce is a natural dietary supplement aimed at enhancing memory, focus, and cognitive function through a blend of ingredients like Ginkgo Biloba and Bacopa Monnieri. It supports cognitive health, reduces brain fog, and boosts mental energy. Available exclusively online, it offers a 180-day money-back guarantee, emphasizing its commitment to quality and customer satisfaction.
Dry Eye Syndrome Market to Grow at 5.9% CAGR Through 2033
Dry Eye Syndrome Market to reach USD 4,808 Million by 2033, growing at a CAGR of 5.9%. North America dominates with a 38.9% share. Emerging trends include precision medicine, advanced diagnostics, and innovative drug delivery systems. Challenges include limited treatment options and high prevalence, especially in aging populations.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath